You have 9 free searches left this month | for more free features.

Beijing (1)

Shanghai (1)

Advanced HCC (1)

Melanoma (1)

Other Solid Tumors (1)

Not yet recruiting (2)

phase 1/phase 2 (2)

Shanghai Kanda Biotechnology Co., Ltd. (2)

kd6001 (2)

bevacizumab (1)

tislelizumab (1)

toripalimab (1)

drug (2)

Industry (2)

Interventional (2)

kd6001

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Not yet recruiting

Jun 13, 2023

Not yet recruiting

Feb 3, 2023